Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT Followed by Resection for Patients With Borderline Resectable Pancreatic Cancer


Original post, click here

Drug: Cyclophosphamide

Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.

Other Name: CY

Drug: Nivolumab

Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.

Other Name: OPDIVO

Drug: GVAX Pancreas Vaccine

Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.

Other Name: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine

Radiation: Stereotactic Body Radiation (SBRT)

SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).